MX2020001590A - Agonistas del receptor de glp-1/glucagon en el tratamiento de la enfermedad del higado graso y la esteatohepetitis. - Google Patents
Agonistas del receptor de glp-1/glucagon en el tratamiento de la enfermedad del higado graso y la esteatohepetitis.Info
- Publication number
- MX2020001590A MX2020001590A MX2020001590A MX2020001590A MX2020001590A MX 2020001590 A MX2020001590 A MX 2020001590A MX 2020001590 A MX2020001590 A MX 2020001590A MX 2020001590 A MX2020001590 A MX 2020001590A MX 2020001590 A MX2020001590 A MX 2020001590A
- Authority
- MX
- Mexico
- Prior art keywords
- time
- liver disease
- fatty liver
- nafld
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2278—Vasoactive intestinal peptide [VIP]; Related peptides (e.g. Exendin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Abstract
La presente invención se refiere al uso médico de agonistas específicos del receptor de GLP-1/glucagón en la prevención y/o tratamiento de la enfermedad hepática metabólica, particularmente enfermedad del hígado graso no alcohólico (NAFLD), más particularmente hígado graso no alcohólico (NAFL), esteatohepatitis no alcohólica (NASH) y/o fibrosis hepática asociada a NAFLD.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17306059 | 2017-08-09 | ||
PCT/EP2018/071478 WO2019030268A1 (en) | 2017-08-09 | 2018-08-08 | GLP-1 / GLUCAGON RECEPTOR AGONISTS FOR THE TREATMENT OF HEPATIC STEATOSIS AND STÉATOHÉPATITE |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020001590A true MX2020001590A (es) | 2020-03-20 |
Family
ID=59761892
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020001590A MX2020001590A (es) | 2017-08-09 | 2018-08-08 | Agonistas del receptor de glp-1/glucagon en el tratamiento de la enfermedad del higado graso y la esteatohepetitis. |
Country Status (15)
Country | Link |
---|---|
US (1) | US11352405B2 (es) |
EP (1) | EP3664833B1 (es) |
JP (1) | JP7230002B2 (es) |
KR (1) | KR20200037358A (es) |
CN (1) | CN111032071A (es) |
AU (1) | AU2018314773A1 (es) |
BR (1) | BR112020002503A2 (es) |
CA (1) | CA3072118A1 (es) |
ES (1) | ES2953631T3 (es) |
IL (1) | IL272457A (es) |
MX (1) | MX2020001590A (es) |
RU (1) | RU2020109881A (es) |
SG (1) | SG11202000941YA (es) |
TW (1) | TW201920240A (es) |
WO (1) | WO2019030268A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN112442114A (zh) * | 2019-08-29 | 2021-03-05 | 渥太华Hdl药物研发公司 | 一种多肽及其应用 |
WO2021204755A1 (en) | 2020-04-06 | 2021-10-14 | Poxel | Pharmaceutical combination for the treatment of liver diseases |
MX2022013230A (es) | 2020-04-24 | 2022-11-14 | Boehringer Ingelheim Int | Analogos de glucagon como agonistas de accion prolongada del receptor de glp-1/glucagon para usarse en el tratamiento de enfermedad del higado graso y esteatohepatitis. |
US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
CN112472794A (zh) * | 2020-11-17 | 2021-03-12 | 深圳市图微安创科技开发有限公司 | 双靶点激动剂多肽治疗anit介导的pbc及其相关的肝纤维化 |
CN117677395A (zh) * | 2021-07-30 | 2024-03-08 | 勃林格殷格翰国际有限公司 | 长效glp1/胰高血糖素受体激动剂的剂量方案 |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2127676A3 (en) * | 2004-11-01 | 2013-09-04 | Amylin Pharmaceuticals, LLC | Treatment of obesity and related disorders |
KR101968344B1 (ko) * | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
AR094181A1 (es) | 2012-12-21 | 2015-07-15 | Sanofi Sa | Agonistas duales de glp1/gip o trigonales de glp1/gip/glucagon |
TW201625668A (zh) * | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物 |
BR112017008160A8 (pt) * | 2014-10-24 | 2023-04-11 | Merck Sharp & Dohme | Peptídeo, composição, métodos para tratamento de um paciente ou indivíduo e para tratamento de uma doença metabólica, e, usos de um peptídeo e de uma composição |
US10752693B2 (en) * | 2015-04-02 | 2020-08-25 | Remd Biotherapeutics, Inc. | Methods for treating obesity and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis using glucagon receptor antagonistic antibodies |
WO2016198628A1 (en) * | 2015-06-12 | 2016-12-15 | Sanofi | Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists |
WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
CN115181175A (zh) * | 2016-04-22 | 2022-10-14 | 深圳市图微安创科技开发有限公司 | Glp-1r/gcgr双靶点激动剂多肽治疗脂肪肝病、高脂血症和动脉硬化 |
TW201832783A (zh) | 2016-12-02 | 2018-09-16 | 法商賽諾菲公司 | 包含glp-1/胰高血糖素雙重激動劑、連接子和透明質酸的接合物 |
-
2018
- 2018-08-08 KR KR1020207006505A patent/KR20200037358A/ko not_active Application Discontinuation
- 2018-08-08 SG SG11202000941YA patent/SG11202000941YA/en unknown
- 2018-08-08 ES ES18749805T patent/ES2953631T3/es active Active
- 2018-08-08 EP EP18749805.0A patent/EP3664833B1/en active Active
- 2018-08-08 TW TW107127569A patent/TW201920240A/zh unknown
- 2018-08-08 MX MX2020001590A patent/MX2020001590A/es unknown
- 2018-08-08 US US16/637,517 patent/US11352405B2/en active Active
- 2018-08-08 BR BR112020002503-8A patent/BR112020002503A2/pt not_active Application Discontinuation
- 2018-08-08 JP JP2020506879A patent/JP7230002B2/ja active Active
- 2018-08-08 WO PCT/EP2018/071478 patent/WO2019030268A1/en active Search and Examination
- 2018-08-08 RU RU2020109881A patent/RU2020109881A/ru not_active Application Discontinuation
- 2018-08-08 CN CN201880051577.1A patent/CN111032071A/zh active Pending
- 2018-08-08 AU AU2018314773A patent/AU2018314773A1/en not_active Abandoned
- 2018-08-08 CA CA3072118A patent/CA3072118A1/en active Pending
-
2020
- 2020-02-04 IL IL272457A patent/IL272457A/en unknown
Also Published As
Publication number | Publication date |
---|---|
US20200216510A1 (en) | 2020-07-09 |
JP2020530017A (ja) | 2020-10-15 |
WO2019030268A1 (en) | 2019-02-14 |
SG11202000941YA (en) | 2020-02-27 |
US11352405B2 (en) | 2022-06-07 |
TW201920240A (zh) | 2019-06-01 |
CA3072118A1 (en) | 2019-02-14 |
JP7230002B2 (ja) | 2023-02-28 |
AU2018314773A1 (en) | 2020-03-26 |
EP3664833A1 (en) | 2020-06-17 |
IL272457A (en) | 2020-03-31 |
RU2020109881A (ru) | 2021-09-10 |
RU2020109881A3 (es) | 2021-12-15 |
EP3664833B1 (en) | 2023-05-31 |
BR112020002503A2 (pt) | 2020-08-18 |
ES2953631T3 (es) | 2023-11-14 |
CN111032071A (zh) | 2020-04-17 |
KR20200037358A (ko) | 2020-04-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020001590A (es) | Agonistas del receptor de glp-1/glucagon en el tratamiento de la enfermedad del higado graso y la esteatohepetitis. | |
PH12020550559A1 (en) | System, cartridge, beverage preparation unit and method for producing a beverage | |
PH12017500502A1 (en) | Therapeutic agent delivery device | |
MY170349A (en) | Nasal delivery devices | |
MX2017006268A (es) | Administracion intranasal. | |
SG10201806300VA (en) | Liquid pharmaceutical composition | |
SG11201808607SA (en) | Medicine obtained by combining fxr agonist and arb | |
MX367674B (es) | Composición farmacéutica de dosis fija estable que comprende mometasona y olopatadina. | |
MX2016014914A (es) | Distribuidor de bomba y sistema que comprende un cartucho de relleno y el distribuidor de bomba. | |
MX2021002892A (es) | Formulaciones orales de agonistas del receptor opioide kappa. | |
GB2467509A (en) | Apparatus and method of massage | |
MX2015014490A (es) | Distribucion de liquidos y metodos para distribuir liquidos. | |
MX346268B (es) | Pistón para un cartucho para el uso en un dispositivo de administración de fármacos. | |
ZA201907520B (en) | Stable liquid formulations of prothioconazole | |
WO2020018792A3 (en) | Drug delivery insertion apparatuses and system | |
NZ717495A (en) | Method and apparatus for treatment of respiratory disorders | |
BR112015007897A2 (pt) | método e dispositivo para transferir uma mensagem e equipamento eletrônico | |
MX2017008000A (es) | Sistema de inyeccion de un solo uso. | |
MX367203B (es) | Manguera de llenado. | |
MX353975B (es) | Formulaciones estables no corrosivas para inhaladores presurizados de dosis medida. | |
EA201691660A1 (ru) | Применение обратно-мицеллярных систем для осуществления доставки хелатирующих агентов радионуклидов и металлов | |
BR112018000018A2 (pt) | dispositivo e sistema de liberação de uso único com aspectos de segurança | |
AR112727A1 (es) | Programación de rellenado de una unidad de dosificación | |
GB2573082A (en) | Liquid treatment dispenser | |
MX2018005318A (es) | Componente espumante. |